Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Skin Cancer
Cell-penetrating peptide selectively kills melanoma cells in study
Scientists have voiced fresh hopes for metastatic skin cancer therapy after identifying a way to kill melanoma cells efficiently and selectively while sparing normal cells, according to a recent study.
September 8, 2023
Castle Biosciences reports study validation for melanoma gene expression test
The study findings support results from a recently published study which showed that patients who received routine imaging guided by high-risk 31-GEP test scores had earlier diagnoses of recurrence, which in turn led to better outcomes for patients.
July 6, 2023
DermTech moves to lay off 40 people, focuses on melanoma test to reduce spending
DermTech is reducing its workforce by 15% as part of a restructuring that will see the company suspend pipeline programs and focus on growing sales of its DMT melanoma test.
June 30, 2023
FDA clears DeepX Diagnostics digital dermatoscope to screen for suspected skin cancer lesions
The device has conducted more than 180 thousand assessments in pharmacies and primary care clinics in Europe; DeepX is poised to enter the U.S. market.
June 6, 2023
SkylineDx, NeraCare partner on melanoma test development
They entered a co-development and licensing agreement for NeraCare’s proteomic test Immunoprint, which identifies patients with early-stage melanoma who are at high risk of progression, relapse, and death.
April 21, 2023
DermTech obtains melanoma testing coverage for additional 1.9 million people
The skin-based genomics test is a noninvasive way to enhance melanoma detection with a greater than 99% negative predictive value, DermTech said.
March 7, 2023
DermTech, Sonora Quest ink deal to broaden access to melanoma detection test
Under the agreement, Sonora Quest becomes the exclusive laboratory provider in Arizona for DermTech’s melanoma test.
November 16, 2022
Castle Biosciences reports results for gene expression tests in melanoma study
Castle Biosciences described studies evaluating its DecisionDx-Melanoma and DecisionDx-UM gene expression profile tests, conducted in collaboration with the National Cancer Institute.
October 27, 2022
Biocept expands commercial availability of CSF assay to metastatic melanoma
The new CNSide for melanoma assay uses an antibody cocktail optimized for the capture of melanoma cells based on unique cellular characteristics.
October 17, 2022
Tempus, Kartos Therapeutics collaborate on CDx for Merkel cell carcinoma treatment
The collaboration is aimed at developing a companion diagnostic (CDx) test to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be responsive to treatment with navtemadlin.
October 7, 2022
Castle Biosciences posts revenue surge, lower net loss in Q2
For the period (end-June 30), Castle had revenue of $34.8 million, up from $22.8 million in the second quarter of 2021. The firm delivered 11,034 total test reports in the second quarter, up 57% compared with the same period last year. Castle also pointed to a 44% increase in skin cancer gene expression report test volume.
August 8, 2022
Labcorp launches skin cancer assay
Studies have shown that LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. Labcorp said its LAG-3 IHC method has demonstrated performance suitable for analysis of LAG-3 immune cell expression in clinical melanoma samples in a study published May 9 in the Journal of Clinical Pathology.
May 18, 2022
Page 1 of 2
Next Page
